Adding Palbociclib Delays Progression in HR-Positive Breast Cancer
In this video we discuss the results of the PALOMA3 trial, which tested fulvestrant and palbociclib in metastatic, hormone receptor–positive HER2-negative breast cancer.
In this video, Nicholas C. Turner, MD, of Royal Marsden Hospital and the Cancer Research Institute in London, discusses the results of the PALOMA3 trial, which tested fulvestrant and palbociclib in metastatic, hormone receptor (HR)-positive HER2-negative breast cancer.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
